Arterial expression of PTH-related protein is markedly induced by angioplasty. PTH-related protein contains a nuclear localization signal (NLS). PTH-related protein mutants lacking the NLS (⌬NLS-PTH-related protein) are potent inhibitors of arterial vascular smooth muscle cell (VSMC) proliferation in vitro. This is of clinical relevance because adenoviral delivery of ⌬NLS-PTH-related protein at angioplasty completely inhibits arterial restenosis in rats. In this study we explored the cellular mechanisms through which ⌬NLS-PTH-related protein arrests the cell cycle. In vivo, adenoviral delivery of ⌬NLS-PTH-related protein at angioplasty markedly inhibited VSMC proliferation as compared with angioplastied carotids infected with control adenovirus (Ad.LacZ). In vitro, ⌬NLS-PTH-related protein overexpression was associated with a decrease in phospho-pRb, and a G 0 /G 1 arrest. This pRb underphosphorylation was associated with stable levels of cdks 2, 4, and 6, the D and E cyclins, p16, p18, p19, and p21, but was associated with a dramatic decrease in cdk-2 and cdk4 kinase activities. Cyclin A was reduced, but restoring cyclin A adenovirally to normal did not promote cell cycle progression in ⌬NLS-PTH-related protein VSMC. More importantly, p15 INK4 and p27 kip1 , two critical inhibitors of the G 1/S progression, were markedly increased. Normalization of both p15 INK4b and p27 kip1 by small interfering RNA knockdown normalized cell cycle progression. These data indicate that the changes in p15 INK4b and p27 kip1 fully account for the marked cell cycle slowing induced by ⌬NLS-PTH-related protein in VSMCs. Finally, ⌬NLS-PTH-related protein is able to induce p15 INK4 and p27 kip1 expression when delivered adenovirally to primary murine VSMCs. These studies provide a mechanistic understanding of ⌬NLS-PTH-related protein actions, and suggest that ⌬NLS-PTH-related protein may have particular efficacy for the prevention of arterial restenosis.
peutic attempts have been directed at arresting cell cycle progression in VSMCs after angioplasty. These have included approaches such as the adenoviral introduction of molecules to enforce cell cycle arrest, e.g. inhibitors of cdk-2 and nonphosphorylatable forms of the retinoblastoma protein, pRb (4 -6) . Another approach has been viral delivery of cell cycle inhibitors such as p21 cip1 or p27 kip1 (7) . p27 kip1 is of particular interest because studies by Boehm et al. (8) have demonstrated that post-angioplasty intimal hyperplasia is particularly aggressive or severe in mice lacking p27 kip1 , and, conversely, replacement of p27 kip1 in p27 kip1 knockout mice markedly attenuates the neointimal response. Similarly, adenoviral delivery of p27 kip1 has markedly attenuated the neointimal response in the rat carotid and pig femoral arteries (7, 9, 10) . Finally, p27 kip1 is believed to be one of the key downstream effector molecules that mediate the inhibition of neointima formation by sirolimus-eluting stents (11) .
PTH-related protein was originally identified in the quest for the humoral agent that causes humoral hypercalcemia of malignancy (12, 13) . It is now appreciated that PTH-related protein is produced ubiquitously, and serves paracrine, autocrine, and intracrine functions to regulate proliferation, differentiation, and death in a broad spectrum of mammalian cell types (14) . Among the plethora of tissues that produce PTH-related protein is the arterial VSMC. We and others have demonstrated that PTHrelated protein is present in VSMCs in all types of vessels, from arterioles to the aorta, and its level of expression is markedly up-regulated by arterial injury and by atherosclerosis (14 -17) . We have also shown that PTH-related protein appears to participate actively in the arterial response to injury because further up-regulation of PTH-related protein by adenoviral overexpression exacerbates neointima formation (18) , and because the rates of VSMC proliferation are attenuated in PTH-related proteinnull mice (19) .
PTH-related protein is a prohormone. Following direction into the endoplasmic reticulum by its signal peptide (SP) (Fig. 1) , it is posttranslationally proteolytically processed into a large family of mature secretory forms, the best characterized of which is PTH-related protein (20, 21) . PTH-related protein also contains a classical bipartite nuclear localization signal (NLS) that is capable of directing PTH-related protein, as well as heterologous fusion proteins, into the nuclear compartment (14, 15, 19, 22, 23) . The cellular mechanisms through which the decision to enter either the secretory pathway or the nuclear targeting pathway have been reviewed (24) , and appear to reside in the selective or alternate use of one of several possible translational initiation sites in the PTH-related protein mRNA.
The functional consequence of these events is that PTH-related protein can have paradoxically opposite effects in a variety of tissues. For example, whereas overexpression of wild-type (i.e. NLS-intact) PTH-related protein leads to acceleration of VSMC proliferation, overexpression of a form of PTH-related protein in which the NLS has been deleted (⌬-NLS-PTH-related protein) paradoxically results in marked slowing of VSMC proliferation (18, 19, 23) . This ability of ⌬-NLS-PTH-related protein to slow or arrest VSMC cycle progression has been documented using [ 3 H]thymidine incorporation (19) , counting VSMC numbers (19, 23) , and flow cytometry (18) , and is associated with an accumulation of the hypophosphorylated form of pRb (18) , and failure to generate phospho-pRb (18) . More importantly, we have taken advantage of this function to demonstrate that adenoviral delivery of ⌬-NLS-PTH-related protein completely prevents the neointima response to injury in the rat carotid injury model (18) .
Thus, at present, whereas it seems clear that ⌬-NLS-PTHrelated protein is capable of arresting VSMC growth in vitro, and of preventing neointima formation in vivo, and that this has obvious potential therapeutic value, the precise cellular mechanisms through which this occurs are unknown. Because we had observed previously that ⌬-NLS-PTH-related protein induces VSMC arrest and failure of pRb phosphorylation (18), we now have performed a comprehensive analysis of the proteins upstream of pRb that regulate the G 1/S transition in a VSMC model, A-10 cells. We report here that ⌬-NLS-PTHrelated protein markedly and specifically up-regulates p15 (18, 19) . C, The adenovirus encoding the ⌬NLS-PTH-related protein structure includes the ⌬NLS-PTH-related protein with a hemagglutinin epitope tag (HA) at the C terminus (18, 19, 23) , a cytomegalovirus (CMV) promoter, and an SV40 poly A signal. The adenovirus preparation and purification are detailed in the Materials and Methods.
Materials and Methods

Cell culture and PTH-related protein-expressing cell lines
The VSM cell line A10, derived from embryonic rat thoracic aorta, was purchased from American Type Culture Collection (Rockville, MD) and cultured in medium with 10% serum as described previously (18, 19, 23) . Cells were stably transfected with pcDNA3 encoding full-length human PTH-related protein(1-139) deleted for its NLS (⌬NLS) and selected as described in detail previously. We have previously demonstrated that stable transfection of A-10 cells with empty vectors pcDNA3 or pLJ has no effect on cell proliferation as assessed using [ 3 H]thymidine, cell counting, or flow cytometry (supplemental Fig. 1 , which is published as supplemental data on The Endocrine Society's Journals Online web site at http://endo.endojournals.org, and Refs. 18, 19, and 23) . Thus, untransfected A-10 cells were used as the control throughout this study. Murine primary aortic VSMCs were isolated and cultured as described previously (25) . They were characterized for smooth muscle actin expression, and only cells that were smooth muscle actin-positive were studied as shown previously.
Cell cycle analysis
Cell cycle distribution was analyzed by flow cytometry, as described previously (18, 25) . All experiments were performed in at least three different lines of control and ⌬NLS-expressing cells, and each was performed on at least three different occasions in triplicate.
Real-time PCR
Total RNA was extracted from appropriate A10 cells using TRIZOL Reagent (Invitrogen Corp., Carlsbad, CA) according to the manufacturer's instructions. Ten micrograms of RNA were treated with deoxyribonuclease I (Ambion, Inc., Austin, TX), and 1 g RNA and 20 pmol random hexamer were then denatured at 70 C for 2 min and cooled on ice. RNA was reverse transcribed using the Advantage RT-for-PCR Kit (BD Biosciences Clontech, Palo Alto, CA). Quantitative PCR was performed using the TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA) on an ABI Prism 7700 Sequence Detector set at 50 C for 2 min, 95 C for 10 min, followed by 40 cycles of 95 C for 15 sec and 60 C for 1 min. The 18S forward oligo was 5Ј-ACATCCAAGGAAGGCAG-CAG-3Ј, reverse oligo was 5Ј-TTCGTCACTACCTCCCCGG-3Ј, and probe was 5Ј-/56-FAM/CGCGCAAATTACCCACTCCCGA/3BHQ/-3Ј. The p27 kip1 forward oligo was 5Ј-GCTTGGATGTCAGCGGGA-3Ј, reverse oligo was 5Ј-TCAGAGTTTGCCTGAGACCCA-3Ј, and the probe was 5Ј-/56-FAM/CGCCAGGCGGTGCCTTCAA/3BHQ/-3Ј. The p15INK4 oligos were 5Ј-GCTCAGAGACGAGGCTGTAACA-3Ј, 5Ј-CAGUCUUCCUAGAUAGGGC-3Ј, and 5Ј-CCGGTCCGTGGCA-GAA-3Ј. The cyclin A oligos were: 5Ј-TGGCTTTTAGTGCCG-CTGTC-3Ј, 5Ј-ACCCGGAGCCAGAAAACCACTGG-3Ј, and 5Ј-CCATCCATTGGATAATCAAGAGG-3Ј. Results are expressed as changes in amounts of p15 
Immunoblot analysis of cell cycle proteins
Cell extracts were prepared, resolved by SDS-PAGE, transferred to Immobilon-P membranes (Millipore, Bedford, MA), and immunoblotted as described in detail previously (18) . Each immunoblot shown in the figures is representative of a minimum of three immunoblots (when no changes were seen on three consecutive occasions), and in most cases five to eight immunoblots.
Kinase assays
cdk4 and cdk2 kinase assays were performed as described previously (25 (18, 23) , human cyclin A, and GFP were ligated into the cytomegalovirus promoter-containing, adenovirus-based plasmid, pACCMV.pLpA (26) . They were then cotransfected with a second plasmid (pJM17) (26) that contained an additional 4 kb of the pBR plasmid interrupting the E1 region and DNA from a replication-defective adenovirus, into human embryonic kidney-293 cells (American Type Culture Collection, Manassas, VA) using Superfect (QIAGEN, Inc., Valencia, CA), according to the manufacturer's instructions. After recombination and lysis of the cells, the medium was collected, and the remaining cells were lysed by freezing and thawing. The cell debris was pelleted, and the viral supernatant was saved for subsequent experiments. Adenovirus DNA was sequenced to confirm the correct orientation and sequence of ␤-galactosidase, ⌬NLS-PTHrelated protein-HA, human cyclin A, and GFP cDNAs. Adenovirus was purified on a CsCl/Tris gradient, separated into aliquots, and stored at Ϫ80 C until use. Multiplicity of infection (MOI) was determined using OD 260 and plaque assay.
Small interfering RNA (siRNA) transfection
Transfections were performed in serum-free medium for 5 h at 37 C with 20 g Lipofectamine (Invitrogen) and with either 150 nM control, 
Fluorescent immunocytochemistry
Cell growing in glass chamber slides were fixed with 4% paraformaldehyde in PBS as described previously (23) . Staining was performed as described previously (23) using an anti-p27 kip1 antiserum (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) diluted 1:250, or an anti-p15 antiserum (Neomarker, Fremont, CA) diluted 1:100, or an anti-hydroxyapatite (HA) antiserum (Cell Signaling Technology, Inc., Danvers, MA).
Quantification of VSMC proliferation in vivo
The experimental protocol was approved by the University of Pittsburgh Institutional Animal Care and Use Committee. Rat carotid angioplasties were performed as described previously (18) . Balloon injury and adenovirus infection were performed on the left common carotid artery of adult Sprague Dawley male rats weighing 450 -600 g. After arteriotomy into the external carotid artery, a 2-French Fogarty balloon catheter (Baxter, Irvine, CA) was inserted into the common carotid artery and inflated with a calibrated inflation device to a pressure of 2 atm for 5 min, and passed back and forth three times. After removing the balloon catheter, the common carotid artery was flushed with PBS before introduction of adenovirus. Recombinant adenovirus stocks were used within 2 h thawing. Fifty microliters of 10 10 plaque-forming units/ml adenoviral vector (Ad.LacZ, or Ad.⌬NLS) or DMEM were instilled into the injured isolated common carotid segment. After 15 min the adenovirus or DMEM was aspirated. The proximal external carotid artery was ligated, and blood flow reestablished. VSMC proliferation in vivo was assessed 4 d after angioplasty. Animals were injected with 5-bromo-2-deoxyuridine (BrdU) (30 mg/kg at 30, 20, and 6 h before being killed), and arteries were perfusion fixed and harvested, paraffin embedded, and sectioned as described previously (18) . Three sections per animal, and six animals per condition, were deparaffinized, rehydrated, and treated in prewarmed 1 M HCl for 1 h at 37 C, blocked in 2% BSA/PBS for 1 h, then incubated overnight with anti-BrdU (Abcam, Cambridge, MA) and antismooth muscle actin antibodies (Santa Cruz Biotechnology). After several washings in PBS containing 1% Tween, slides were incubated for 1 h with secondary antibodies, gel mounted, and coverslipped. Three fields per section were quantified for BrdU-and smooth muscle-positive cells.
Statistics
Statistical analysis in Figs. 5, D and E; 8, B, D, and G; 9, A, C, and E; and 10C was performed using one-way ANOVA followed by a Holm-Sidak comparison vs. a control group. A one-way ANOVA followed by a Holm-Sidak pairwise comparison was performed in Figs. 2B, 5F, and 8B. For Figs. 3A; 4; 5; B and C; 6, B and C; and 7, B and C, a Student's t test was used. All values are expressed as means Ϯ SEM. P values less than or equal to 0.05 were considered significant and are detailed in each correspondent figure.
Results
⌬-NLS-PTH-related protein induces cell cycle arrest in vivo
We have shown previously that adenoviral delivery of NLS-PTH-related protein leads to nearly complete abrogation of neointima formation in angioplastied rat carotids. We have also shown previously that stable transfection of A10 cells with ⌬-NLS-PTH-related protein induces cell cycle arrest (18, 19, 23) . Thus, we first wanted to determine whether adenoviral delivery of ⌬-NLS-PTH-related protein also was able to inhibit VSMC proliferation in vivo after vascular injury. Therefore, we studied the VSMC proliferation rate (using BrdU incorporation) in rat carotid arteries 4 d after balloon injury. As shown in Fig. 2 , the BrdU incorporation rate was almost undetectable in uninjured arteries. In contrast, BrdU incorporation increased 10-to 15-fold in angioplastied control (DMEM or Ad.LacZ) arteries. However, adenoviral delivery of ⌬NLS-PTH-related protein led to a marked 70% reduction in BrdU incorporation in VSMCs, compared with DMEM or Ad.LacZ-treated arteries. These data indicate that in vivo, as previously shown in vitro, overexpression of ⌬NLS-PTH-related protein markedly inhibits VSMC proliferation.
⌬-NLS-PTH-related protein has little effect on the pocket proteins or the D/E cyclin family
We next wanted to determine the cell cycle mechanisms underlying this VSMC cycle arrest induced by ⌬NLS-PTHrelated protein. As can be seen in Fig. 3 , and as reported previously (18), ⌬NLS-PTH-related protein overexpression resulted in G 0 /G 1 arrest in A10 cells, associated with a loss of the hyperphosphorylated form of pRb. In contrast, there was no significant change in the levels of the other two pocket proteins, p107 and p130, in the three D cyclins, or in their partners, cdks 4 or 6, cyclin E and its partner cdk-2.
cdk-2 kinase activity is markedly reduced in ⌬-NLS-PTH-related protein-expressing A-10 cells
The observation that pRb was hypophosphorylated (Fig. 3B ) in the absence of quantitative changes in the molecules directly upstream of Rb suggested that the activity of cdk-4/6 or cdk-2 must have been reduced by ⌬-NLS-PTH-related protein overexpression. Figure 4 demonstrates that this is true. cdk-4 kinase activity was reduced by approximately 40%, and cdk-2 kinase activity was reduced by approximately 70%, and both were statistically significant.
Cyclin A is reduced, but restoring cyclin A to normal does not accelerate cell cycle progression in ⌬-NLS-PTHrelated protein VSMCs
Because cdk-2 activity is regulated by cyclin A as well as cyclin E, we examined cyclin A levels. As can be seen in Fig.  5 , cyclin A levels were markedly reduced in ⌬NLS-PTH-related protein A-10 cells, and cyclin A mRNA was also reduced, although not as strikingly as cyclin A protein. To determine whether cyclin A loss could be the cause of cell cycle arrest, we restored cyclin A levels to normal using a cyclin A-expressing adenovirus (Fig. 5, D and E) . As shown in Fig. 5 , D-F, 400 MOI was sufficient to normalize cyclin A to normal levels, yet, restoring cyclin A levels was not able to induce cell cycle acceleration in ⌬NLS-PTH-related protein-expressing A-10 cells. Thus, other upstream factors must be responsible for Rb hypophosphorylation. Ad.GFP (lane 7) has no effect on cyclin A expression, whereas ⌬NLS-PTH-related proteinoverexpressing A-10 cells exposed to increasing MOI of Ad.cyclin A (lanes 3-6) display escalating expression of cyclin A. E, Densitometric analysis of cyclin A immunoblots. The delivery of 400 MOI of Ad.cyclin A was able to restore normal control levels of cyclin A expression in VSMC overexpressing ⌬NLS-PTH-related protein. *, P Ͻ 0.05 vs. A10 ϩ Ad.GFP400; ns, nonsignificant vs. A10ϩ Ad.GFP400. F, Flow cytometry of A-10 cells and ⌬NLS-PTH-related protein overexpressing A-10 cells, and the effects of 400 MOI of Ad.GFP and Ad.cyclin A on cell cycle progression in A-10 cells overexpressing ⌬NLS-PTHrelated protein and control A10 cells. *, P Ͻ 0.05 vs. G 1 /G 0 in A10ϩ Ad.GFP400; #, P Ͻ 0.05 vs. S in A10ϩ Ad.GFP400; #, P Ͻ 0.05 vs. S in A10ϩ Ad.GFP400; §, P Ͻ 0.05 vs. G 2 /M in A10ϩ Ad.GFP400; ns, nonsignificant vs. NLS ϩ Ad.GFP400. Note that Ad.GFP has no effect on cell cycle distribution in slowly cycling A-10 cells overexpressing ⌬NLS-PTH-related protein. In contrast, ⌬NLS-PTH-related protein-overexpressing A-10 cells that lack cyclin A are not accelerated by the 400 MOI Ad.cyclin A. However, 400 MOI of Ad.cyclin A was able to accelerate A10 cell cycle, suggesting that the cyclin A delivered adenovirally is fully active and able to drive proliferation as expected. 
INK4b is up-regulated in ⌬-NLS-PTH-related protein-expressing A-10 cells
cdk-4 activity is regulated by a family of cyclin-dependent kinases. Therefore, these were examined. As shown in Fig. 6 , p15
INK4b is markedly and specifically up-regulated in ⌬-NLS-PTH-related protein-expressing cells, both at the protein and mRNA levels, whereas the remaining INK4 family members were unaffected. Figure 6D shows that p15
INK4b is also dramatically increased as assessed using immunocytochemistry.
p27 kip1 is also increased by ⌬-NLS-PTH-related protein overexpression
Because cdk-4 and cdk-2 activity can be modulated by the CIP/KIP family of cell cycle inhibitors, we also examined p21 were not affected in ⌬NLS-PTH-related protein-overexpressing A-10 cells. In contrast, p27 kip1 was markedly increased at the protein and mRNA levels, as demonstrated by immunoblot, quantitative RT-PCR, and immunocytochemistry (Fig. 7) . Immunocytochemistry also demonstrated that the majority of p27 kip1 is located in the nuclear compartment, where it would be expected to inhibit cell cycle progression. were able to restore fully the elevated p15 INK4b and p27 kip1 protein levels to normal. In contrast, siRNA ctls had no effect on either p15
Normalization of p15
INK4b or p27 kip1 . Importantly, siRNAs simultaneously directed against both p15
INK4b and p27 kip1 were able to normalize coordinately the levels of both p15
INK4b and p27 kip1 . Figure 8E shows that the introduction of siRNAs directed against either p15
INK4b or p27 kip1 individually led to cell cycle acceleration in ⌬-NLS-PTH-related protein-expressing A-10 cells, but normalization of either cell cycle inhibitor individually did not appear to fully normalize cell cycle kinetics. In contrast, combined introduction of siRNAs against both p15
INK4b and p27 kip1 fully restored the flow cytometric profile to normal. Finally, Fig. 8 , F and G, shows that cyclin A levels were restored in ⌬NLS-PTHrelated protein expressing cells treated with p27 siRNA and/or p15 siRNA. Together, these findings are consistent with both p15
INK4b and p27 kip1 playing an individual role in cell cycle slowing induced by ⌬-NLS-PTH-related protein. They also indicate that the combined changes in p15
INK4b and p27 kip1 fully account for the marked cell cycle slowing induced by ⌬-NLS-PTHrelated protein.
PTH-related protein(1-36) added exogenously up-regulates p27
kip1 but not p15
INK4b
Amino-terminal forms of PTH-related protein have induced cell cycle arrest and decreased [ 3 H]thymidine incorporation when applied to VSMCs (18, 19) . In addition, amino-terminal PTH-related protein decreases Rb phosphorylation and increases p27 kip1 expression (27) . None of the other secretory forms of PTH-related protein, such as midregion and C-terminus forms, is able to induce VSMC cycle arrest (19) . ⌬NLS-PTHrelated protein constructs contain the SP, and would therefore be expected to lead to secretion of amino-terminal forms of PTHrelated protein. Indeed, we have demonstrated that this is the case (18, 19, 23) . Therefore, we determined whether PTH-related protein (1-36) , added exogenously for 24 h, would upregulate simultaneously both cell cycle inhibitors, p15
INK4b and Figure 9A shows that, as expected, addition of PTHrelated protein(1-36) for 24 h inhibits VSMC proliferation. Similarly and as a control, addition of a nondegradable form of cAMP, db-cAMP, leads to a significant cell cycle arrest. However, addition of PTH-related protein(1-36) or bd-cAMP only marginally increases p27 kip1 expression, and not p15 INK4b . This suggests that the paracrine/autocrine effect of a secreted amino-terminal form of PTH-related protein does not fully account for the up-regulation of both p27 kip1 and p15 INK4b , and therefore, for the cell cycle arrest by ⌬-NLS-PTH-related protein.
Adenoviral delivery of an ⌬NLS-PTH-related protein to murine primary VSMCs inhibits proliferation, and induces p15
INK4b and p27 kip1 expression Data described previously were obtained using rat A10 VSMCs. However, these data depended solely on the overexpression of ⌬NLS-PTH-related protein and then selection of stably transfected cells. Therefore, we wanted to know if the conclusions drawn from these systems applied to primary cells. They were characterized for smooth muscle actin expression, and only cells that were smooth muscle actin-positive were studied (Fig. 10A) . As shown in Fig. 10B , progressively increasing Ad.⌬NLS-PTH-related protein MOI in primary cultures of mouse aortic VSMCs progressively increased the expression of an ⌬NLS-PTH-related protein. This increased overexpression of ⌬NLS-PTH-related protein was accompanied by a progressive increase in both p15 and p27 expression (Fig.  10, C and D) , leading to progressive cell cycle deceleration (Fig. 10C) . Collectively, these results confirm, in primary cells, the cell cycle arrest induced ⌬NLS-PTH-related protein overexpression, as seen in vivo (Fig. 2) and in A10-VSMC line (Fig. 3) . These results also confirm, in primary VSMCs in general, the induction of two critical cell cycle inhibitors, as seen in A10 VSMCs.
Discussion
The ⌬NLS mutant of PTH-related protein is a potent inhibitor of cell cycle progression in VSMCs, and also has potent effects to prevent neointima progression in vivo (18) . Here, we illustrate that the ⌬-NLS mutant of PTH-related protein is a potent inhibitor of cell cycle progression in vivo. In A-10 VSMCs, this is associated with an inability to phosphorylate the key checkpoint control protein, pRb.
More importantly, we demonstrate that this inhibition of cell cycle progression results from an increase in the level of expression of two cell cycle inhibitors, one of which, p27 kip1 , is well documented to be a cell cycle inhibitor in VSMCs, and the other of which, p15 INK4b , is less well appreciated to inhibit arterial smooth muscle proliferation. To the best of our knowledge, this is the first agent that is able to up-regulate coordinately these two cell cycle inhibitors.
As noted in the introductory section, p27 kip1 is a widely acknowledged inhibitor of VSMC cycle progression (7-10). Its loss is associated with an exaggerated neointimal response in mouse aortic angioplasty models, and its restoration by bone marrow transplantation in p27 kip1Ϫ/Ϫ mice restores the neointimal response to that of normal animals (8) . In addition, p27 kip1 delivery using adenovirus has resulted in a 52% reduction in the neointimal response to angioplasty in pig arteries (7) . Finally, up-regulation of p27 kip1 is believed to be one of the mechanisms through which the sirolimus used in drug-eluting stents is able to attenuate the neointimal response to angioplasty (11) . Thus, the observations that p27 kip1 up-regulation results in a reduction in cdk-2 kinase activity and pRb hypophosphorylation are entirely consistent with existing models of VSMC cycle regulation. On the other hand, the observation that ⌬-NLS-PTH-related protein dramatically up-regulates p27 kip1 is entirely novel. This has not been reported previously in VSMCs or any other tissue type.
In nonvascular systems, p15 INK4b , as well as other members of the INK4 family, is well recognized as a direct inhibitor of cdk-4 and cdk-6 activity, and, by displacing p21 cip1 and p27 kip1 from cdk4/6 cyclin D complexes onto cdk-2-cyclin E complexes, can serve as an inhibitor of cdk-2 activity (28 -30) . In contrast to p27 KIP1 , INK4 members like p16 are not detectable in normal arteries, and their expression changes minimally after vascular injury (7) . Recently, adenoviral overexpression of p15
Ink4 has reduced VSMC growth by 60% in vitro and inhibited in-stent VSMC proliferation and intimal hyperplasia in vivo (31) . Interestingly, McArthur (9) and Tsui (10) et al. have reported that the combined delivery of a p27-p16 fusion gene appears to be a more potent inhibitor of VSMC proliferation in vitro and a superior inhibitor of neointima hyperplasia in vivo than either inhibitor alone. These studies suggest that drugs that induce combined up-regulation of INK 4 and CIP/KIP inhibitors might permit a particularly efficient inhibition of neointima formation. ⌬NLS-PTH-related protein appears to act in precisely this manner.
The observations that two cell cycle inhibitors are specifically and markedly up-regulated in VSMCs in response to ⌬NLS-PTH-related protein are consistent with, but do not prove, that p15
INK4b and p27 kip1 are the proximal causes of cell cycle arrest. Documentation of this comes from the siRNA knockdown ex- periments, which clearly demonstrate that restoration of both p15 INK4b and p27 kip1 to normal levels fully restores the attenuated cell cycle kinetics of the ⌬NLS-PTH-related protein-expressing A-10 cells to those of normal A-10 cells. These observations make it clear that it is the ⌬NLS-PTH-related protein-mediated increase in p15 INK4b and p27 kip1 that causes cell cycle arrest or slowing in VSMCs.
⌬NLS-PTH-related protein also induced a dramatic reduction in cyclin A. This might be expected to reduce or interfere with S-phase progression because cyclin A is an important partner for cdk-2 in late S phase. However, complete restoration of cyclin A protein to normal levels had no effect on cell cycle progression in ⌬-NLS-PTH-related protein-expressing A-10 cells. This indicates that although cyclin A loss occurred, it was not responsible for the slowing or arrest of ⌬-NLS-PTH-related protein-expressing A-10 cells. Although we have not explored this directly, it seems likely that the reduction in cyclin A is a response to upstream events because cyclin A is a transcriptional target of E2Fs (32, 33) .
These studies have therapeutic implications for angioplasty and arterial restenosis. First, they provide a mechanistic explanation as to how ⌬-NLS-PTH-related protein delivery so dramatically prevents the previously reported neointimal response to angioplasty in the rat carotid (18) . Second, they demonstrate that ⌬-NLS-PTH-related protein activates two separate cell cycle inhibitors, and may therefore provide additional efficacy to agents such as sirolimus that activate p27 kip1 . Third, they suggest that ⌬-NLS-PTH-related protein may itself have therapeutic promise in the growing armamentarium of agents that prevent arterial restenosis (1) .
On the other hand, these studies have a number of limitations. First, these studies do not shed light on how ⌬-NLS-PTH-related protein regulates p15
INK4b and p27 kip1 . In essence, there are two potential mechanisms: paradigm A, in which secreted aminoterminal PTH-related protein fragments such as PTH-related protein(1-36) might interact with the PTH-PTH-related protein receptor in an autocrine/paracrine pathway and inhibit VSMC proliferation (19, 27, 34) ; or paradigm B, in which PTH-related protein, devoid of its NLS, might serve an as yet unidentified dominant-negative function, e.g. by interfering with the normal nuclear transit, and pro-proliferative actions of endogenous PTH-related protein, thereby inhibiting VSMC proliferation. In favor of paradigm A, amino-terminal forms of PTH-related protein have induced cell cycle arrest and decreased [ 3 H]thymidine incorporation when applied to VSMCs (27, 34) . In addition, amino-terminal PTH-related protein decreases Rb phosphorylation and increases p27 kip1 expression (27) . Furthermore, ⌬NLS-PTH-related protein constructs contain the SP and would therefore be expected to lead to secretion of amino-terminal forms of PTH-related protein, which we have shown to be true (18, 23) . In favor of paradigm B, Fig. 9 demonstrates that the addition of PTH-related protein(1-36), added exogenously, does only increase p27 kip1 expression but not p15
INK4b
, suggesting that there might be an additional, dominant negative effect of ⌬NLS to inhibit VSMC proliferation. Extensive future studies are needed to distinguish definitely between these two possibilities.
A second limitation is that to date, these observations are limited to rat A10 and murine VSMCs in vitro and in rat in vivo. It remains to be demonstrated whether ⌬-NLS-PTH-related protein will be effective in other species, including humans. Studies are in progress to address these issues, and preliminary data indicate that adenoviral delivery of ⌬-NLS-PTH-related protein to angioplastied pig iliac arteries is similarly effective (N.F.-T. and A.F.S., unpublished observations). Human coronary VSMCs have markedly up-regulated PTH-related protein in response to arterial injury (16, 17) .
In summary, these studies make the novel observations that p15
INK4b and p27 kip1 are markedly, specifically, and coordinately up-regulated in VSMCs in response to ⌬-NLS-PTH-related protein, and that in combination, they can fully account for the cell cycle arrest induced by ⌬-NLS-PTH-related protein. Although further studies are required to define fully the pathways through which ⌬-NLS-PTH-related protein inhibits VSMC cycle progression and inhibits the neointimal response to arterial injury in vivo, these studies provide the mechanistic underpinnings for understanding how ⌬-NLS-PTH-related protein functions, and suggest that ⌬-NLS-PTH-related protein may have particular efficacy for the prevention of arterial restenosis. 
